Acorda Signs Settlement With Mylan on Generic Ampyra
03 Agosto 2018 - 8:39AM
Noticias Dow Jones
By Michael Dabaie
Biotechnology company Acorda Therapeutics Inc. (ACOR) on Friday
said it signed a conditioned settlement agreement with Mylan N.V.
(MYL) and affiliates over Acorda's multiple-sclerosis drug
Ampyra.
Under the settlement agreement, Mylan will be permitted to
market its generic version of Ampyra in the U.S. sometime in 2025
or earlier under certain circumstances, Acorda said in a filing
with the Securities and Exchange Commission.
Acorda also said it signed interim agreements with Teva
Pharmaceutical Industries Ltd. (TEVA) and Hikma Pharmaceuticals PLC
(HKMPY) concerning their patent litigation relating to Ampyra.
Acorda is awaiting a decision of the U.S. Court of Appeals for
the Federal Circuit in its appeal of a 2017 U.S. district court
decision that invalidated four of its Ampyra patents set to expire
between 2025 and 2027.
Acorda earlier this week reiterated it sees Ampyra 2018 net
revenue of $330 million to $350 million.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
August 03, 2018 09:24 ET (13:24 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Hikma Pharmaceuticals (PK) (USOTC:HKMPY)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Hikma Pharmaceuticals (PK) (USOTC:HKMPY)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Hikma Pharmaceuticals plc (PK) (OTCMarkets): 0 recent articles
Más de Hikma Pharmaceuticals Plc. (PC) Artículos de Noticias